Clinical trialNCT04853134WithdrawnPhase 3Interventional

Proxalutamide Treatment for COVID-19 Female Outpatients

SponsorApplied Biology, Inc.Enrollment0Covid19SARS-CoV Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Andy Goren, MD
Applied Biology, Inc.
Study Director
clinicaltrials.gov ↗
Carlos Wambier, MD
Applied Biology, Inc.
Principal Investigator
clinicaltrials.gov ↗
Flavio Cadegiani, MD
Corpometria Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil

Corpometria Institute
Brasília, Brazil

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Proxalutamide

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Nov 2020
Primary completion: 1 Dec 2021
Completion: 1 Dec 2021
Last update posted: 4 Mar 2022
Registered enrollment: 0
Registry id: NCT04853134

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.